Metsera (NASDAQ:MTSR) Shares Gap Up on Analyst Upgrade

Shares of Metsera, Inc. (NASDAQ:MTSR - Get Free Report) gapped up before the market opened on Tuesday after Guggenheim raised their price target on the stock from $56.00 to $62.00. The stock had previously closed at $30.39, but opened at $32.35. Guggenheim currently has a buy rating on the stock. Metsera shares last traded at $37.42, with a volume of 959,269 shares traded.

A number of other analysts also recently commented on the stock. Evercore ISI started coverage on shares of Metsera in a research report on Tuesday, February 25th. They set an "outperform" rating on the stock. Cantor Fitzgerald started coverage on shares of Metsera in a research report on Tuesday, February 25th. They set an "overweight" rating on the stock. Finally, Bank of America started coverage on shares of Metsera in a report on Tuesday, February 25th. They issued a "buy" rating and a $38.00 target price on the stock.

Institutional Trading of Metsera

A number of hedge funds and other institutional investors have recently made changes to their positions in MTSR. Bank of New York Mellon Corp bought a new stake in shares of Metsera in the 1st quarter worth approximately $884,000. New York State Common Retirement Fund bought a new stake in shares of Metsera in the 1st quarter worth approximately $131,000. Alphabet Inc. bought a new stake in shares of Metsera in the 1st quarter worth approximately $135,059,000. Massachusetts Financial Services Co. MA bought a new stake in shares of Metsera in the 1st quarter worth approximately $13,111,000. Finally, Jennison Associates LLC bought a new stake in shares of Metsera in the 1st quarter worth approximately $9,679,000.

Metsera Trading Down 15.0%

The company has a fifty day moving average of $24.39.

Metsera (NASDAQ:MTSR - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($1.03) earnings per share for the quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.